Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC)

8119 Background: : Through its superior activity, improved safety and convenience, × (Xeloda®) is replacing 5-FU/LV as the backbone of MCRC therapy and is now moving into the adjuvant setting. In a...